Hyunho LEE
Chief Technology Officer and Head of R&D VSPharmTech
Seminars
Thursday 29th January 2026
Modulating DDR in GBM to Enable Radiosensitizer-Driven Combination Strategies
10:30 am
• See how VSPharmTech is developing VS-101 to enable radiosensitizer-driven strategies in glioblastoma
• Clarifying synthetic lethality and combination strategies in GBM
• Exploring regulatory and orphan drug designation progress
